The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Adults: A Six-Month Study
Open accessAbstract
Background: Pimecrolimus cream (Elidel®, SDZ ASM 981), a non-steroid inhibitor of inflammatory cytokines, is effective in the treatment of atopic dermatitis (AD). We assessed whether early treatment of AD signs/symptoms reduces the need for topical corticosteroids. Objective: To investigate the efficacy and safety of pimecrolimus cream 1% in the long-term management of adult AD. Methods: 192 adults with moderate to severe AD were randomised (1:1) for twice daily (b.i.d.) treatment of early signs or symptoms of AD with either pimecrolimus cream 1% or vehicle cream (control group) to prevent progression to flares. Treatment was given as needed for 24 weeks. In the event of flares, a moderately potent corticosteroid (prednicarbate 0.25% cream) was permitted as rescue medication in both groups. The percentage of days on which a topical corticosteroid was used to treat disease flares was the main outcome measure. Results: Corticosteroid medication was used on 14.2% (95% confidence interval, CI: 8.3–21.1) of the days of the 24-week treatment period in the pimecrolimus group and on 37.2% (95% CI: 30.4–44.0) of the days in the control group (p < 0.001). In total, 44.8% (43/96) of patients in the pimecrolimus group did not experience a flare compared with 18.8% (18/96) of patients in the control group. The median time to first flare was 144 days in the pimecrolimus group and 26 days in the control group (p < 0.001). Pimecrolimus treatment was also associated with improvement in signs and symptoms of AD, pruritus, patients’ self-assessment and quality of life. Conclusions: Pimecrolimus cream 1% b.i.d. is an effective, well-tolerated, long-term treatment for AD in adults, substantially reducing the number of flares compared to a conventional therapy and consequently reducing or eliminating the need for corticosteroid treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Cited by
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Guidelines of care for atopic dermatitis
Hanifin, J. M., Cooper, K. D., Ho, V. C., Kang, S., Krafchik, B. R., Margolis, D. J., Schachner, L. A., Sidbury, R., Whitmore, S. E., Sieck, C. K., et al. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.08.003 · Cited by 387
ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis
Darsow, U., Wollenberg, A., Simon, D., Taïeb, A., Werfel, T., Oranje, A., Gelmetti, C., Svensson, A., Deleuran, M., Calza, A., et al. (2010) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03415.x · Cited by 307
Ashcroft, D. M., Dimmock, P., Garside, R., Stein, K., & Williams, H. C. (2005) · BMJ · doi:10.1136/bmj.38376.439653.d3 · Cited by 294
Metadata
- Authors
- Meurer, M., Fölster-Holst, R., Wozel, G., Weidinger, G., Jünger, M., Bräutigam, M., & for the CASM-DE-01 Study Group, F.
- Venue
- Dermatology
- Publisher
- S. Karger AG
- Published
- 2002
- Volume
- 205
- Issue
- 3
- Pages
- 271-277
- ISSN
- 1018-8665 (ISSN-L)
- 1421-9832
- OpenAlex
- W1988528294
- Cited by
- 218
- References
- 1
- FWCI
- 19.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Adults: A Six-Month Study. https://app.cochat.ai/papers/10.1159/000065863
- The paper
- Meurer, M., Fölster-Holst, R., Wozel, G., Weidinger, G., Jünger, M., Bräutigam, M., & for the CASM-DE-01 Study Group, F. (2002). Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Adults: A Six-Month Study. Dermatology. https://doi.org/10.1159/000065863
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.